Disparities by Socioeconomic Status and Diagnosis of Dementia in the Prescribing of Antipsychotics in a Real-World Data Population Over 60 Years of Age

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2024 Jun 29

PMID 38943388

Authors

Javier Mar

Uxue Zubiagirre

Igor Larranaga

Myriam Soto-Gordoa

Lorea Mar-Barrutia

Ana Gonzalez-Pinto

Oliver Ibarrondo

Affiliations

Soon will be listed here.

Abstract

Background: Antipsychotics are widely used in the elderly due to the high prevalence of neuropsychiatric associated with dementia.

Objective: To analyze potential disparities in antipsychotic use in the general population of Gipuzkoa by socioeconomic status (SES) and diagnosis of Alzheimer's disease and related dementia (ADRD) adjusting for somatic and psychiatric comorbidities, age, and sex.

Methods: A retrospective observational study was carried out in all the 221,777 individuals over 60 years of age (Gipuzkoa, Spain) to collect diagnosis of ADRD, the Charlson Comorbidity Index, and psychiatric comorbidities considering all primary, outpatient, emergency and inpatient care episodes and first- and second-generation antipsychotics, and sociodemographic variables, namely, age, sex, SES and living in a nursing home. Logistic regression was used for multivariate statisticalanalysis.

Results: Use of any antipsychotic was greater in women, individuals over 80 years old, living in a nursing home, with a diagnosis of dementia, somatic and psychiatric comorbidities, and low SES. Quetiapine was the most used drug. The likelihood of any antipsychotic use was significantly associated with low SES (odds ratio [OR]: 1.60; confidence interval [CI]: 1.52-1.68), age over 80 years (OR: 1.56; CI: 1.47-1.65), institutionalization (OR: 12.61; CI: 11.64-13.65), diagnosis of dementia (OR: 10.18; CI: 9.55-10.85) and the comorbidities of depression (OR: 3.79; CI: 3.58-4.01) and psychosis (OR: 4.96; CI: 4.64-5.30).

Conclusions: The greater levels of antipsychotic use and institutionalization in people of low SES indicate inequity in the management of neuropsychiatric symptoms. Increasing the offer of non-pharmacological treatments in the health system might help reduce inequity.

References

. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023; 71(7):2052-2081. DOI: 10.1111/jgs.18372. View

Mar J, Arrospide A, Soto-Gordoa M, Machon M, Iruin A, Martinez-Lage P . Validity of a computerised population registry of dementia based on clinical databases. Neurologia (Engl Ed). 2021; 36(6):418-425. DOI: 10.1016/j.nrleng.2018.03.005. View

Charlson M, Carrozzino D, Guidi J, Patierno C . Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom. 2022; 91(1):8-35. DOI: 10.1159/000521288. View

van Bussel E, Richard E, Arts D, Nooyens A, Coloma P, de Waal M . Dementia incidence trend over 1992-2014 in the Netherlands: Analysis of primary care data. PLoS Med. 2017; 14(3):e1002235. PMC: 5340347. DOI: 10.1371/journal.pmed.1002235. View

Zhao Q, Tan L, Wang H, Jiang T, Tan M, Tan L . The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. J Affect Disord. 2015; 190:264-271. DOI: 10.1016/j.jad.2015.09.069. View

van der Linde R, Stephan B, Matthews F, Brayne C, Savva G . Behavioural and psychological symptoms in the older population without dementia--relationship with socio-demographics, health and cognition. BMC Geriatr. 2010; 10:87. PMC: 3014957. DOI: 10.1186/1471-2318-10-87. View

Perera G, Pedersen L, Ansel D, Alexander M, Arrighi H, Avillach P . Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimers Dement. 2017; 14(2):130-139. DOI: 10.1016/j.jalz.2017.06.2270. View

Afram B, Stephan A, Verbeek H, Bleijlevens M, Suhonen R, Sutcliffe C . Reasons for institutionalization of people with dementia: informal caregiver reports from 8 European countries. J Am Med Dir Assoc. 2013; 15(2):108-16. DOI: 10.1016/j.jamda.2013.09.012. View

Onor M, Saina M, Aguglia E . Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia. Am J Alzheimers Dis Other Demen. 2007; 21(6):448-53. DOI: 10.1177/1533317506294775. View

10.

Davies S, Burhan A, Kim D, Gerretsen P, Graff-Guerrero A, Woo V . Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. J Psychopharmacol. 2018; 32(5):509-523. PMC: 5944080. DOI: 10.1177/0269881117744996. View

11.

Gitlin L, Hodgson N, Jutkowitz E, Pizzi L . The cost-effectiveness of a nonpharmacologic intervention for individuals with dementia and family caregivers: the tailored activity program. Am J Geriatr Psychiatry. 2010; 18(6):510-9. PMC: 2938079. DOI: 10.1097/JGP.0b013e3181c37d13. View

12.

Kivimaki M, Gunnell D, Lawlor D, Davey Smith G, Pentti J, Virtanen M . Social inequalities in antidepressant treatment and mortality: a longitudinal register study. Psychol Med. 2006; 37(3):373-82. DOI: 10.1017/S0033291706009457. View

13.

Alexopoulos G, Streim J, Carpenter D, Docherty J . Using antipsychotic agents in older patients. J Clin Psychiatry. 2004; 65 Suppl 2:5-99. View

14.

Majoka M, Schimming C . Effect of Social Determinants of Health on Cognition and Risk of Alzheimer Disease and Related Dementias. Clin Ther. 2021; 43(6):922-929. DOI: 10.1016/j.clinthera.2021.05.005. View

15.

Mar J, Gorostiza A, Ibarrondo O, Cernuda C, Arrospide A, Iruin A . Validation of Random Forest Machine Learning Models to Predict Dementia-Related Neuropsychiatric Symptoms in Real-World Data. J Alzheimers Dis. 2020; 77(2):855-864. PMC: 7592688. DOI: 10.3233/JAD-200345. View

16.

Tariot P, Salzman C, Yeung P, Pultz J, Rak I . Long-Term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000; 22(9):1068-84. DOI: 10.1016/s0149-2918(00)80085-5. View

17.

Puyat J, Law M, Wong S, Sutherland J, Morgan S . The essential and potentially inappropriate use of antipsychotics across income groups: an analysis of linked administrative data. Can J Psychiatry. 2012; 57(8):488-95. DOI: 10.1177/070674371205700807. View

18.

Ponjoan A, Garre-Olmo J, Blanch J, Fages E, Alves-Cabratosa L, Marti-Lluch R . Epidemiology of dementia: prevalence and incidence estimates using validated electronic health records from primary care. Clin Epidemiol. 2019; 11:217-228. PMC: 6407519. DOI: 10.2147/CLEP.S186590. View

19.

Aguera-Ortiz L, Babulal G, Bruneau M, Creese B, DAntonio F, Fischer C . Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. J Alzheimers Dis. 2022; 88(4):1203-1228. PMC: 9484097. DOI: 10.3233/JAD-215483. View

20.

Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E . Alzheimer's disease. Lancet. 2011; 377(9770):1019-31. DOI: 10.1016/S0140-6736(10)61349-9. View